A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

Trial Details

NCT ID
NCT06010875
Phase
PHASE1
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • CD70 CAR-T cells
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • Age ≥18 years old, male or female;
  • Advanced/metastatic solid tumor confirmed by histopathology or cytology (paraffin section or fresh biopsy tumor tissue specimen) (positive tumor CD…
  • At least after TKI/PARPi, anti-vascular drug treatment is ineffective, there is no available standard treatment plan or standard treatment fails or…
  • Measurable and evaluable lesions defined by RECIST version 1.1: Measurable disease is defined as at least one lesion that can be accurately measure…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →